The Community for Open Antimicrobial Drug Discovery (CO-ADD) at The University of Queensland’s Institute for Molecular Bioscience (IMB) and the Innovative Medicines Initiative (IMI) ENABLE project have aligned to develop potential new antibiotics against multi-drug resistant bacterial infections.

Protagonist Therapeutics, a spin-out company from IMB, has begun clinical trials with a novel drug candidate being investigated as a potential 'oral targeted therapy' for inflammatory bowel diseases.

The Australian Research Council has awarded five new Future Fellows at The University of Queensland, including IMB's Dr Sonia Henriques whose research has huge potential in reducing global carbon emissions.

The CO-ADD Chemistry Prize is an online competition open to all academic researchers and students worldwide, who can submit an abstract and an optional video on how chemistry can fight the war on superbugs and help find the next antibiotic. Entries close 15 January 2016.

The University of Queensland announced today that it is a Grand Challenges Explorations winner, an initiative funded by the Bill & Melinda Gates Foundation. Research groups led by Professor Paul Young of the School of Chemistry and Molecular Biosciences, and Professor Matt Cooper at UQ’s Institute for Molecular Bioscience will pursue an innovative global health and development research project, titled Next-gen diagnostics for field-based surveillance of Wolbachia and arboviral infections in wild mosquitoes.

The University of Queensland has teamed up with the Queensland Department of Health to bring researchers and clinicians together to take action against antibiotic resistance.

Research to investigate drug leads for cholesterol, antibiotics for drug-resistant bacteria, cardiovascular development, and inflammation are just some of the innovative projects at UQ’s Institute for Molecular Bioscience (IMB) to receive new funding from the National Health and Medical Research Council (NHMRC).